Inebilizumab improves outcome in patients generalized myasthenia gravis
1. In patients with myasthenia gravis (MG) who had anti-acetylcholine receptor antibodies or anti-muscle-specific kinase antibodies, intravenous inebilizumab reduced disease...
Rheumatology
Upadacitinib with glucocorticoids superior to glucocorticoids alone for giant cell arteritis remission
1. In this randomized trial, upadacitinib dosed at 15mg with a 26-week glucocorticoid taper showed superior efficacy than placebo with...
Obinutuzumab plus standard therapy is efficacious in managing active lupus nephritis
1. In this randomized trial, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete...
Poor baseline lung function associated with increased risk of incident tuberculosis
1. The risk of tuberculosis (TB) was higher in individuals with obstructive or restrictive lung function impairment compared to those...
Vaccinations may be associated with small but temporary changes in menstrual cycle length
1. Influenza vaccine given alone or concurrently with a COVID-19 vaccine was associated with a small (< 1 day) but...
Alcohol use disorder may be associated with human immunodeficiency virus
Alcohol Use Disorder Diagnoses Among Individuals Who Take HIV Preexposure Prophylaxis 1. In this cohort of individuals taking preexposure prophylaxis...
Risk of bloodstream infections with indwelling peripheral catheters increase after 3 days
1. The risk of bloodstream infections (BSIs) in individuals with indwelling peripheral intravenous catheters (PIVCs) is significantly increased after 3...
Inebilizumab reduces the risk of flares in IgG4-related disease
1. In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased the likelihood...
Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related...
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission...